Skip to content
DataLookout
Menu

NCT07803653

IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Start date pushed from Oct 31, 2026 to Dec 31, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Treatment-related unexpected grade 3 or higher toxicity
Timeframe: Up to 28 days post infusion
Incidence of adverse events
Timeframe: Up to 28 days post infusion
Prostate cancer response
Timeframe: Up to 1 year post infusion

Secondary (7)

Progression free survival
Overall survival
Objective response rate
Stable disease
Clinical benefit
Show 2 moreShow less
Overall response
Prostate specific antigen (PSA) response

Arms and interventions

Treatment (chemotherapy, FH-STEAP1 IL-18 CAR T cells)Experimental

Patients undergo leukapheresis. Patients receive cyclophosphamide intravenously (IV) and fludarabine IV on days -5 to -3. Patients receive FH-STEAP1 IL-18 CAR T cell IV on day 0. Patients may continue to receive androgen deprivation therapy per standard of care, throughout the study. Patients undergo nuclear medicine bone scan, CT scan, MRI and/or PET scan, tumor biopsy and blood sample collection throughout the study. Patients may also undergo MUGA scan or echocardiography during screening.

Biologicals: FH-STEAP1 IL-18 CAR T cells

Drugs: Antiandrogen Therapy, Cyclophosphamide, Fludarabine

Procedures: Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Biopsy Procedure

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States